Form D · Pharmaceuticals

Avilar Therapeutics, Inc.

Waltham, MA · CIK 0001836740

Offering snapshot reported Feb 13, 2023 · SEC filing

Reported sold
$75.3M
Offering amount: $75.3M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 14, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$37.6M$75.3MDec 17, 2020: $20,276,164.00Dec 17, 2020Feb 13, 2023: $75,276,164.00Feb 13, 2023

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$20,276,164 → $75,276,164
  • Reported investors3 → 5

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 13, 2023Amendment$75,276,164$55,000,000vs Dec 17, 20205SEC filing
Dec 17, 2020Initial$20,276,164No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-383553

Source: Form D, filed Feb 13, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Theresa Cameron Director
Milind Deshpande Director
Martin Freed Director
Phil Graham Executive
Daniel Grau Director, Executive
Paulina Hill Director
Adam Muzikant Executive
David Neafus Executive
Joshua Resnick Director
Stephanie Tozzo Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
400 Totten Pond Road Suite 110
Waltham, MA, 02451